<DOC>
	<DOCNO>NCT01643083</DOCNO>
	<brief_summary>Functional dyspepsia common medical condition , occur 30 % people community . However , result current pharmacological treatment functional dyspepsia unsatisfactory . Rifaximin minimally absorb antibiotic used treatment non-constipated irritable bowel syndrome ( IBS ) . In particular , bloat abdominal pain improve rifaximin treatment group IBS patient . Whilst considerable overlap symptom functional dyspepsia IBS , investigator test whether rifaximin also effective cure post-prandial distress symptom related dyspepsia .</brief_summary>
	<brief_title>Rifaximin Functional Dyspepsia</brief_title>
	<detailed_description>The aim study test effect rifaximin , minimally absorbed antibiotic , symptom patient functional dyspepsia .</detailed_description>
	<mesh_term>Dyspepsia</mesh_term>
	<mesh_term>Gastritis</mesh_term>
	<mesh_term>Rifaximin</mesh_term>
	<mesh_term>Rifamycins</mesh_term>
	<criteria>Nonulcer dyspeptic patient fulfill postprandial distress syndrome accord Rome III Criteria Active dyspeptic symptom Normal upper endoscopy Urea Breath Test Rapid urease test Not typical gastroesophageal reflux biliary colic symptom , presence infrequent acid reflux allow No active dyspeptic symptom Allergic rifaximin Recent antibiotic use past 8 wk Recent PPI H2RA past 4 wk On anticoagulant , anticonvulsant oral contraceptive On NSAIDs , aspirin Clopidogrel Pregnancy breast feed Previous gastric surgery</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>Post-prandial distress syndrome</keyword>
</DOC>